This study's primary objective is to test the hypothesis that a single infusion of
subcutaneous lidocaine can cause a clinically useful reduction in cancer pain within 48 hours
of infusion and lasting a minimum of 7 days. A clinically useful reduction in pain is defined
by either a 2-point reduction (on a 0-10 scale) in the worst pain experienced over a 24-hour
period, or a ≥30% reduction in 24-hour opioid requirement. We will use a composite endpoint
of reduction in pain without increase in 24-hr opioid requirement or no decrease in pain with
a ≥30% reduction in 24-hour opioid requirement.Subjects will receive either lidocaine or
placebo, followed at least 1 week later by the alternate agent.